Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)

The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and auto…

Chronic Immune ThrombocytopeniaAutoimmune Hemolytic Anemia

Estimated

~$10 – $8,750

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07603557